{"id":389323,"date":"2023-12-21T14:11:14","date_gmt":"2023-12-21T19:11:14","guid":{"rendered":"https:\/\/platohealth.ai\/despite-use-of-tecovirimat-since-the-beginning-of-the-2022-mpox-outbreak\/"},"modified":"2023-12-21T15:43:59","modified_gmt":"2023-12-21T20:43:59","slug":"despite-use-of-tecovirimat-since-the-beginning-of-the-2022-mpox-outbreak","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/despite-use-of-tecovirimat-since-the-beginning-of-the-2022-mpox-outbreak\/","title":{"rendered":"Despite use of tecovirimat since the beginning of the 2022 mpox outbreak,","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

Despite use of tecovirimat since the beginning of the 2022 mpox outbreak, few data have been published on its antiviral effect in humans; this study predicts the impact of early tecovirimat administration on the time to viral clearance in patients with mpox infection, using an integrative modeling approach combining pre-clinical and clinical data<\/strong><\/p>\n

Credit: Team BIPID, Universit\u00e9 Paris Cit\u00e9 (CC-BY 4.0, https:\/\/creativecommons.org\/licenses\/by\/4.0\/)<\/p>\n

\n

Despite use of tecovirimat since the beginning of the 2022 mpox outbreak, few data have been published on its antiviral effect in humans; this study predicts the impact of early tecovirimat administration on the time to viral clearance in patients with mpox infection, using an integrative modeling approach combining pre-clinical and clinical data<\/strong><\/p>\n

#####<\/p>\n

In your coverage, please use this URL to provide access to the freely available paper in PLOS Biology<\/em>:   <\/strong>http:\/\/journals.plos.org\/plosbiology\/article?id=10.1371\/journal.pbio.3002249<\/p>\n

Article Title: <\/strong>Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection<\/p>\n

Author Countries<\/strong>: France, Spain, United Kingdom, United States, Papua New Ginea<\/p>\n

Funding: <\/strong>BTN received funding from IAME UMR 137, Universit\u00e9 Paris Cit\u00e9, INSERM, F-75018, Paris, France (https:\/\/www.iame-research.center\/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.<\/p>\n

\n
\n
\n
\n
\n

Journal<\/h4>\n

PLoS Biology<\/p>\n<\/div>\n

\n

DOI<\/h4>\n

10.1371\/journal.pbio.3002249 <\/i><\/p>\n<\/div>\n

\n

Method of Research<\/h4>\n

Computational simulation\/modeling<\/p>\n<\/div>\n

\n

Subject of Research<\/h4>\n

Not applicable<\/p>\n<\/div>\n

\n

COI Statement<\/h4>\n

Competing interests: I have read the journal\u2019s policy and the authors of this manuscript have the following competing interests: DWG, DEH, and ATR work for SIGA Technologies Inc. Other authors declare no conflicts of interests.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n